Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Merus N.V. CS (NQ: MRUS ) 49.66 -1.27 (-2.49%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Merus N.V. CS < Previous 1 2 3 4 5 Next > Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC May 06, 2024 If approved, Zeno will be the first targeted therapy for NRG1+ cancer From Merus N.V. Via GlobeNewswire Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting April 24, 2024 From Merus N.V. Via GlobeNewswire Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 April 08, 2024 From Merus N.V. Via GlobeNewswire Expert Ratings for Merus November 28, 2023 Via Benzinga The Latest Analyst Ratings for Merus October 24, 2023 Via Benzinga 10 Analysts Have This to Say About Merus September 14, 2023 Via Benzinga Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Merus N.V. Via GlobeNewswire Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers March 06, 2024 From Gilead Sciences, Inc. Via Business Wire Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression March 05, 2024 Poster presentation: Monday, April 8, 2024, 9:00 am-12:30 p.m. PT From Merus N.V. Via GlobeNewswire Where Merus Stands With Analysts August 10, 2023 Via Benzinga Expert Ratings for Merus July 24, 2023 Via Benzinga Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference March 04, 2024 From Merus N.V. Via GlobeNewswire Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update February 28, 2024 From Merus N.V. Via GlobeNewswire Merus to Participate in Upcoming Investor Conferences January 31, 2024 From Merus N.V. Via GlobeNewswire Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023 December 02, 2023 MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24 From Merus N.V. Via GlobeNewswire Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023 November 26, 2023 From Merus N.V. Via GlobeNewswire Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update November 02, 2023 From Merus N.V. Via GlobeNewswire Merus to Participate in Upcoming Investor Conferences November 01, 2023 From Merus N.V. Via GlobeNewswire Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer October 23, 2023 From Merus N.V. Via GlobeNewswire Merus Announces Business Update Conference Call October 15, 2023 From Merus N.V. Via GlobeNewswire New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review October 13, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023 October 06, 2023 From Merus N.V. Via GlobeNewswire Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases September 26, 2023 FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The... Via FinancialNewsMedia AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst September 11, 2023 On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients Via Benzinga Merus to Participate in Upcoming Investor Conferences August 31, 2023 From Merus N.V. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023 August 21, 2023 Via Benzinga Merus Announces Pricing of Public Offering of Common Shares August 09, 2023 From Merus N.V. Via GlobeNewswire Merus N.V. Announces Proposed Public Offering of Common Shares August 09, 2023 From Merus N.V. Via GlobeNewswire Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update August 07, 2023 From Merus N.V. Via GlobeNewswire Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023 July 28, 2023 From Merus N.V. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
